# Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

> **NCT04734379** · PHASE2 · UNKNOWN · sponsor: **Woolsey Pharmaceuticals** · enrollment: 15 (estimated)

## Conditions studied

- Progressive Supranuclear Palsy
- Corticobasal Syndrome

## Interventions

- **DRUG:** Fasudil

## Key facts

- **NCT ID:** NCT04734379
- **Lead sponsor:** Woolsey Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-22
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2022-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04734379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04734379, "Rho Kinase (ROCK) Inhibitor in Tauopathies - 1". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04734379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*